Albain K S, Crowley J J, LeBlanc M, Livingston R B
Loyola University Medical Center, Maywood, IL.
J Clin Oncol. 1990 Sep;8(9):1563-74. doi: 10.1200/JCO.1990.8.9.1563.
We analyzed the 2,580-patient Southwest Oncology Group (SWOG) small-cell lung cancer data base from 1976 to 1988 in order to (1) determine the prognostic value of favorable demographic and tumor-related factors and therapy programs using Cox multivariate analyses in limited- and extensive-stage disease (LD, ED), and (2) define patient subgroups with significantly different survivals using recursive partitioning and amalgamation (RPA) analysis to refine the current two-stage system. Cox multivariate models were applied to 1,363 patients in six LD trials: good performance status, female sex, age less than 70 years, white race, and normal lactate dehydrogenase (LDH) were significant favorable independent predictors. Concurrent chemoradiotherapy was also a strong independent predictor of survival. For 1,217 patients in four ED trials, a normal LDH, treatment with an intensive multidrug regimen, and a single metastatic lesion were favorable independent variables in the Cox model. RPA analysis of 1,137 patients in recent LD and ED trials resulted in a regression tree in which the most important prognostic split was LD versus ED. Normal or abnormal LDH, absence or presence of a pleural effusion, and age less than 70 or greater than or equal to 70 years were important in LD, but only LDH was significant in ED. The terminal nodes of the regression tree were amalgamated to form four distinct prognostic subgroups with median survivals of 19.0, 12.5, 10.5, and 6.3 months (P less than .0001). The best survival occurred for younger patients with "true" LD: no effusion and normal LDH. The two intermediate patient subgroups had either LD or ED but still lived significantly longer than those patients with true ED (elevated LDH). This analysis suggests that although several factors were independent prognostic variables in LD in the Cox models, a smaller number of variables can be used to form important prognostic subgroups through RPA. The LDH emerged as a highly significant factor, but performance status and sex did not. A refinement of the current staging system should be made if our results can be confirmed with a combined-group data base analysis.
我们分析了1976年至1988年西南肿瘤协作组(SWOG)的2580例小细胞肺癌数据库,目的是:(1)使用Cox多变量分析确定有利的人口统计学和肿瘤相关因素及治疗方案在局限期和广泛期疾病(LD、ED)中的预后价值;(2)使用递归分割合并法(RPA)分析定义生存情况有显著差异的患者亚组,以完善当前的两阶段系统。Cox多变量模型应用于六项局限期试验中的1363例患者:良好的体能状态、女性、年龄小于70岁、白种人以及乳酸脱氢酶(LDH)正常是显著的有利独立预测因素。同步放化疗也是生存的有力独立预测因素。对于四项广泛期试验中的1217例患者,LDH正常、采用强化多药方案治疗以及单个转移病灶是Cox模型中的有利独立变量。对近期局限期和广泛期试验中的1137例患者进行的RPA分析得出一棵回归树,其中最重要的预后分割是局限期与广泛期。LDH正常或异常、有无胸腔积液以及年龄小于70岁或大于等于70岁在局限期很重要,但在广泛期只有LDH显著。回归树的终末节点合并形成四个不同的预后亚组,中位生存期分别为19.0、12.5、10.5和6.3个月(P<0.0001)。“真正”局限期的年轻患者生存最佳:无胸腔积液且LDH正常。两个中间患者亚组为局限期或广泛期,但仍比真正广泛期(LDH升高)的患者生存时间显著更长。该分析表明,虽然在Cox模型中几个因素是局限期的独立预后变量,但通过RPA可以用较少数量的变量形成重要的预后亚组。LDH成为一个高度显著的因素,但体能状态和性别并非如此。如果我们的结果能通过联合组数据库分析得到证实,应改进当前的分期系统。